Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annovis Bio, Inc. (ANVS) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Annovis is a late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, and its filings offer detailed insight into its clinical programs, financial condition, capital structure, and governance.
Through periodic reports and current reports on Form 8‑K, Annovis discloses material events such as registered direct offerings of common stock and pre‑funded warrants under its Form S‑3 shelf registration statement, the intended use of proceeds for the continued clinical development of buntanetap and general corporate purposes, and engagement terms with placement agents. Other 8‑K filings describe leadership changes, including appointments and resignations in finance roles, annual meeting voting results, and matters such as NYSE listing compliance plan acceptance.
Investors following Annovis’ late-stage clinical activities can also use SEC filings to connect financial updates with the company’s development plans. Earnings-related 8‑K filings furnish press releases that summarize research and development expenses, general and administrative costs, and net loss figures for specified reporting periods, alongside narrative corporate updates on the pivotal Phase 3 Alzheimer’s trial and other clinical milestones.
On this page, users can review real-time updates as new filings appear on EDGAR, including future annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and additional 8‑K disclosures. AI-powered tools on the platform can help summarize lengthy documents, highlight key sections on topics such as financing terms, clinical development priorities, or listing status, and make it easier to navigate complex language. For those analyzing ANVS, this filings archive is a primary source for understanding how Annovis reports its progress, risks, and obligations in connection with the development of buntanetap and its broader corporate activities.
Annovis Bio, Inc. (NYSE: ANVS) filed an 8-K on June 19, 2025 to disclose that the New York Stock Exchange has accepted the company’s previously submitted listing-compliance plan. The plan was required after Annovis fell out of compliance with NYSE continued-listing standards; acceptance removes the immediate risk of delisting and starts a defined remediation timetable. The 8-K furnishes, but does not file, a press release (Exhibit 99.1) announcing the NYSE decision. No financial statements, earnings data or major transactions were included, and the disclosure is made solely under Item 7.01 (Regulation FD) with no impact on historical financial reporting.
Investors should note that, while acceptance is a constructive step, Annovis must still meet the milestones outlined in the compliance plan to regain full compliance. The filing contains no new operational or financial metrics.
Annovis Bio (ANVS) Vice President of Finance Andrew Walsh reported a new acquisition of company shares on Form 4. The transaction details include:
- Acquired 500 shares of Common Stock
- Purchase price: $2.90 per share
- Transaction date: June 16, 2025
- Total transaction value: $1,450
- Ownership type: Direct
Following this transaction, Walsh holds 500 shares directly. The purchase represents an initial position for the executive, as no prior holdings were reported. The transaction was reported within the required two-business-day filing window, with the Form 4 being filed on June 28, 2025. No derivative securities were involved in this transaction.